Endocrine Therapy Plus Ovarian Suppression Remains An Effective Treatment Strategy in HR+, HER2-, Early Breast Cancer
Findings from the ADAPTcycle trial suggest that endocrine therapy plus ovarian suppression can generate high response rates in patients with hormone receptor-positive early breast cancer, regardless of age.
Investigators Present Real-World Experiences With T-DXd Following HER2 Status Changes
Trastuzumab deruxtecan showed the longest time to next treatment in patients with HER2-positive breast cancer or with stable HER2-low disease among the primary and metastatic setting.
Maintenance Pembrolizumab/Olaparib Falls Short in Locally Advanced, Metastatic TNBC
The median overall survival with pembrolizumab/olaparib was 25.1 months vs 23.4 months with pembrolizumab plus chemotherapy.
Neoadjuvant Pembrolizumab Improves pCR Across ER+ Breast Cancer Subgroups
Different subsets of patients with estrogen receptor-positive breast cancer achieved better pathologic complete response rates with neoadjuvant pembrolizumab/chemotherapy vs placebo/chemotherapy.
Tucatinib Continues to Show Benefit in Pretreated HER2+ Breast Cancer With Brain Metastases
The primary analysis of the phase 3 HER2CLIMB-02 demonstrates that tucatinib slowed disease progression in patients with HER2-positive metastatic breast cancer, including those with brain metastases.
Ribociclib Plus Endocrine Therapy Continues to Perform Well Across MONALEESA-2, -3, and -7 Trials
A consistent progression-free and overall survival benefit was reported among patients with hormone receptor-positive, HER2-negative advanced breast cancer, regardless of age.
Patient-Reported Outcomes From CAPItello-291 Trial Support Capivasertib/Fulvestrant in HR+, HER2- Advanced Breast Cancer
Patients with aromatase inhibitor-resistant HR-positive/HER2-negative advanced breast cancer reported positive outcomes following treatment with capivasertib plus fulvestrant.
Experts Make the Case for More Inclusive Lung Cancer Screening Guidelines
A smoking-duration cutoff may be a better measure for determining lung cancer screening eligibility compared with smoking pack-years.
Opinion: CAR T-Cell Therapy Remains a Promising Therapeutic Option Despite FDA Inquiry into Secondary Malignancies
Oncology nurses should be ready to offer informative guidance to patients and their families concerning the ongoing FDA inquiry and its potential impact.
Newer Urothelial Cancer Drugs Are Effective But Pricey
Frontline treatment with enfortumab vedotin/pembrolizumab is associated with the highest healthcare costs for patients with locally advanced or metastatic urothelial carcinoma.
FDA Launches Priority Review of Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Cancer
The FDA has granted enfortumab vedotin plus pembrolizumab priority review status for patients with locally advanced or metastatic urothelial cancer following data from the phase 3 EV-302/KEYNOTE-A39 trial.
Managing Brain Metastases in a Patient With HER+ Breast Cancer
Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.
Cadonilimab/Chemotherapy Meets Primary End Point in Phase 3 AK104-303 Trial
Frontline cadonilimab (AK104) and platinum-based chemotherapy improved progression-free survival in patients with recurrent or metastatic cervical cancer.
FDA Grants Pirtobrutinib Accelerated Approval to Treat CLL/SLL in the Third Line
The FDA has approved the non-covalent BTK inhibitor, pirtobrutinib, to treat patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already undergone 2 lines of therapy.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Biosimilars Make Routine Prophylaxis With G-CSF Feasible in HER2+ Breast Cancer
The increasing use of biosimilars makes prophylaxis with growth factor more cost effective.
Tenets of Counseling Cancer Survivors During Remission
Experts with the University of Miami Sylvester Comprehensive Cancer Center share their insights.
FDA Is Investigating Potential Secondary Cancer Risks Associated CAR T-Cell Therapy
There have been reports of T-cell malignancies among patients who have undergone CD19- or BCMA-directed autologous CAR T-cell immunotherapies.
Why a Trauma-Informed Approach Is Ideal in Gynecologic Cancer Care
Christina M. Wilson, PhD, CRNP, WHNP-BC, shares how providers can help their patients feel empowered during their treatment.
Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer
Finding ways to prevent and manage stress may be key to optimizing clinical outcomes in oncology.
FDA OKs Nirogacestat for Adults Patients With Desmoid Tumors
The FDA has approved nirogacestat as a treatment for adults with progressing desmoid tumors based off findings from the phase 3 DeFi trial.
PRO-TECT Trial Shows That ePROs May Be Feasibly Implemented Into Routine Oncology Practice
Electronic patient-reported outcomes may have a place in high-quality cancer care, according to investigators.
Lenalidomide/Rituximab Induces Durable Responses in Mantle Cell Lymphoma in 9-Year Follow-Up
The combination of lenalidomide and rituximab led to a median progression-free survival of 9 years—with 17 ongoing responses—among patients with mantle cell lymphoma.
Pembrolizumab Plus Enzalutamide and ADT Falls Short in mHSPC
Pembrolizumab, in addition to enzalutamide and androgen deprivation therapy, was not associated with better radiographic progression-free survival outcomes in patients with metastatic hormone-sensitive prostate cancer.
Olaparib Misses Mark in Recurrent Platinum-Sensitive Ovarian Cancer
Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.
Copanlisib Will No Longer Be Available in the US for Relapsed Follicular Lymphoma
Manufacturers have announced that they will be withdrawing the new drug application for copanlisib in adult patients with relapsed follicular lymphoma.
Investigators Highlight Benefits of Outpatient Delivery of Intensive Chemotherapy
Delivering intensive chemotherapy in the outpatient setting may preserve quality of life and lead to significant cost savings, according to investigators.
Patients With Prostate Cancer Report Better Quality of Life With 18 Months of ADT vs 36 Months
Patients with prostate cancer who received 18 months of androgen deprivation therapy were more likely to recover their serum testosterone levels and to recover quicker than those who received 36 months of therapy.
LINE-1-ORF1p Is a Promising Biomarker for Early Cancer Detection, But More Research Is Needed
Oncology nurses can help patients understand the potential benefit of ORF1p testing for early cancer detection and its current limitations.
Using ctDNA MRD Monitoring During Active Metastatic CRC Treatment
Holly Chitwood, DNP, APRN, FNP-C, AGACNP-BC, shares her real-world experience with circulating-tumor-DNA monitoring in the colorectal cancer setting.
2 Clarke Drive Cranbury, NJ 08512